Indaptus Therapeutics Inc (NASDAQ:INDP) — Market Cap & Net Worth
Market Cap & Net Worth: Indaptus Therapeutics Inc (INDP)
Indaptus Therapeutics Inc (NASDAQ:INDP) has a market capitalization of $2.89 Million ($2.89 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29515 globally and #5942 in its home market, demonstrating a -53.43% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Indaptus Therapeutics Inc's stock price $1.29 by its total outstanding shares 2242324 (2.24 Million). See how much does Indaptus Therapeutics Inc reinvest in capital to understand how much of operating cash flow is reinvested back into capital assets.
Indaptus Therapeutics Inc Market Cap History: 2015 to 2026
Indaptus Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $961.51 Million to $2.89 Million (-41.88% CAGR).
Index Memberships
Indaptus Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #867 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #2749 of 3165 |
Weight: Indaptus Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Indaptus Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Indaptus Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of INDP by Market Capitalization
Companies near Indaptus Therapeutics Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Indaptus Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Indaptus Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Indaptus Therapeutics Inc's market cap moved from $961.51 Million to $ 2.89 Million, with a yearly change of -41.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.89 Million | -55.67% |
| 2025 | $6.53 Million | +245.56% |
| 2024 | $1.89 Million | -52.15% |
| 2023 | $3.95 Million | +21.38% |
| 2022 | $3.25 Million | -74.56% |
| 2021 | $12.78 Million | -58.70% |
| 2020 | $30.94 Million | -65.50% |
| 2019 | $89.69 Million | -93.37% |
| 2018 | $1.35 Billion | +46.41% |
| 2017 | $923.84 Million | -9.65% |
| 2016 | $1.02 Billion | +6.34% |
| 2015 | $961.51 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of Indaptus Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.89 Million USD |
| MoneyControl | $2.89 Million USD |
| MarketWatch | $2.89 Million USD |
| marketcap.company | $2.89 Million USD |
| Reuters | $2.89 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Indaptus Therapeutics Inc
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and h… Read more